This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice. Boehringer Ingelheim Limited has reviewed the scope of the webinar, commissioned the speakers, and approved all materials related to the webinar. The speakers have been paid an honorarium. The views and opinions of the speakers are not necessarily those of Guidelines in Practice, its publisher, advisers, or advertisers. No part of this webinar may be reproduced in any form without the permission of the publisher.

This webinar contains promotional material.

View Trajenta® (linagliptin) prescribing and adverse events reporting information for:
Great Britain 

Northern Ireland

Complete the feedback form and/or download your CPD certificate here

This promotional webinar will:

  • discuss the value and positioning of dipeptidyl peptidase-4 inhibitors (DPP-4i) both within current guidelines and the evolving NHS landscape
  • highlight changes in adult type 2 diabetes care in response to the ongoing COVID-19 pandemic
  • present a series of hypothetical type 2 diabetes case studies with different clinical scenarios.

Wasim Hanif_v3

Dr Kanumilli

Professor Wasim Hanif 
Professor of Diabetes and Endocrinology
Head of Service Diabetes – University Hospital Birmingham
Board of Trustees Diabetes UK

 

Dr Naresh Kanumilli
Community Diabetes Consultant – MUFT
Clinical Champion – Diabetes UK
Clinical Network Lead for Diabetes – Greater Manchester
Primary Care Research Lead – Diabetes for GMCRN

 

Feedback from live webinar attendees

’Thank you, very informative and has improved my confidence in suggesting DPP-4 inhibitors’

’Well-presented and timed’

’Case studies were very beneficial. I liked the speakers discussing them and saying the reasons behind their decisions’

’Excellent and very helpful scenario based presentation. Thank you’

PC-GB-103485

Date of preparation: July 2021